Bedaquiline fumarate

Revision as of 23:36, 25 December 2013 by Gerald Chi (talk | contribs)
Jump to navigation Jump to search
Bedaquiline
SIRTURO® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Microbiology
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Overview

Bedaquiline is a diarylquinoline anti-tuberculosis drug, which was discovered by a team led by Koen Andries at Janssen Pharmaceutica.[1] It is the first new medicine to fight TB in more than forty years,[2][3] and is specifically approved to treat multi-drug-resistant tuberculosis.

Category

Antimycobacterial

US Brand Names

Sirturo®

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | How Supplied | Other Size Packages Available | Labels and Packages

Mechanisms of Action

Bedaquiline affects the proton pump for ATP synthase. This mechanism is unlike that of the quinolones, whose target is DNA gyrase.[4]

References

  1. de Jonge MR, Koymans LH, Guillemont JE, Koul A, Andries K (2007). "A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910". Proteins. 67 (4): 971–80. doi:10.1002/prot.21376. PMID 17387738. Unknown parameter |month= ignored (help)
  2. "FDA Approves 1st New Tuberculosis Drug in 40 Years". ABC News. Retrieved 31 December 2012.
  3. "F.D.A. Approves New Tuberculosis Drug". New York Times. Retrieved 31 December 2012.
  4. Kotz J (2005). "Targeting tuberculosis". Nature Chemical Biology. doi:10.1038/nchembio002. Unknown parameter |month= ignored (help)